The Fund Grade · free · no account needed

What grade does SOPAX get?

Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.

C

Fundprints Fund Grade · as of 2026-09-01

ClearBridge Dividend Strategy Fund Class A

#234 of 440 graded active funds · value · large segment peer group

The point · specialist footprint

SOPAX sits mid pack for specialist backing among graded funds.

Bottom 20%

Bottom 40%

● Middle

Top 40%

Top 20%

beat the S&P in 22% of quarters+3.8 pts/qtr better · 43% beat rate

The middle rungs sat between the extremes, and the pattern was monotonic: every step up in specialist backing came with better subsequent results. Not damning, not compelling. The fee decides whether it is worth it.

2,825 graded funds · 2.7 years of filings, measured as they were published · evidence, not advice

3 funds in the same segment carry an A — members see the names and what they charge. See the alternatives →

The grade scores this fund's specialist share — the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.

Conviction exposure

25.1%

of the book in specialist-converged names

Late-stage weight

22%

of the book in Crowded or Fading names

Active share

86.7%

how far it strays from the index

The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.

Inside the book — top names by stage · as of 2026-09-09

Early Conviction
PSA 2.3%WM 1.7%
Consensus
WMB 4.7%XOM 3.8%MSFT 3.6%+20 locked
Emerging
CMCSA 2.3%
Crowded
APO 2.7%CVS 1.7%VMC 1.6%+3 locked
Fading
AVGO 2.9%TMUS 2.1%SRE 2.1%+6 locked

We email you the day it crosses 50% crowded, and where you stand every month.

Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.

The read · what to do with it

SOPAX earns a C grade, ranking 234 out of 440 funds, with specialist investors holding only 25% of the book. Five positions including AVGO, TMUS, and AMT are in Fading stage, meaning proven specialists are already leaving. The bright spots are CMCSA, PSA, and WM, where specialists are still building early positions.

Watch the combined 9.8% weight in Fading positions like AVGO and AMT, as specialist exits there warrant close monitoring.

Three higher graded funds exist in this same segment, and ClearBridge offers higher graded options within its own family.

Support leaving these positions

AVGO 2.9% of the fund · Fading

APO 2.7% of the fund · Crowded

TMUS 2.1% of the fund · Fading

SRE 2.1% of the fund · Fading

AMT 2% of the fund · Fading

Where it's genuinely early

CMCSA 2.3% of the fund · Emerging

PSA 2.3% of the fund · Early Conviction

WM 1.7% of the fund · Early Conviction

Read from today's disclosed book. Evidence, not advice.

The evidence base updates this week.

The specialists — not the whales — are already positioned for what comes next. Stop finding out last.

Create your free account

No card required · open the feed in 30 seconds